Roman Hrusovsky

ARCH Venture Partners Announces Appointment of Kevin Hrusovsky as Venture Partner

Retrieved on: 
Thursday, May 25, 2023
Roman Hrusovsky, Ohio State University, New England, Professional corporation, Ohio University, CALP, Executive, Drug development, University, Framingham State University, DuPont, ARCH Venture Partners, Medicine, ARCH, PerkinElmer, PKI, Caliper Life Sciences, Health, Management

CHICAGO, May 25, 2023 /PRNewswire/ -- ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner.

Key Points: 
  • CHICAGO, May 25, 2023 /PRNewswire/ -- ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner.
  • "Kevin has been instrumental in the success of multiple ARCH portfolio companies, and we look forward to building the next generation of companies together," said ARCH Co-founder and Managing Director Keith Crandell.
  • "ARCH is committed to bringing the best entrepreneurs, experience, value-add perspective, and network to advance our portfolio companies.
  • Kevin has deep experience in the industry and is an important addition to the ARCH team."

Quanterix to Participate in Barclays Global Healthcare Conference

Retrieved on: 
Wednesday, March 9, 2022
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Cardiology, Private Securities Litigation Reform Act, Research, Inflammation, Webcast, U.S. Securities and Exchange Commission, Conference, Quality of life, Infection, News, Roman Hrusovsky, Risk, Science, Neurology, Technology, Population, EST, Longevity, Corporation, Forward-looking statement

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present in-person at the Barclays Global Healthcare Conference on March 15, 2022 at 10:45 a.m., EST.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present in-person at the Barclays Global Healthcare Conference on March 15, 2022 at 10:45 a.m., EST.
  • A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations .
  • Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
  • Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health.

Quanterix to Participate in The Cowen 42nd Annual Health Care Conference On March 9

Retrieved on: 
Thursday, March 3, 2022
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, EST, Private Securities Litigation Reform Act, Corporation, Longevity, Research, Science, Population, Forward-looking statement, Quality of life, U.S. Securities and Exchange Commission, Infection, News, Shimon Cowen, Webcast, Conference, Inflammation, Roman Hrusovsky, Risk, Technology, Cardiology, Neurology, NASDAQ

Hrusovsky will also host virtual one-on-one meetings with institutional investors on Tuesday, March 8 and Wednesday, March 9.

Key Points: 
  • Hrusovsky will also host virtual one-on-one meetings with institutional investors on Tuesday, March 8 and Wednesday, March 9.
  • A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations .
  • Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
  • Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health.

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

Retrieved on: 
Tuesday, March 1, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Investor, Executive, Neuro, Diagnosis, Deloitte, Achievement, News, PET, Board, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Webcast, FY, Eli Lilly, Roman Hrusovsky, Neurodegeneration, Telecommunication, RUO, NASDAQ, AFL, Biogen, University, Lists of diseases, PerkinElmer, Industry, Company, Lund University, Antibody, EMERGE, Pathology, Disease, Pfizer, Food, Data, Eli Lilly and Company, Emergency Use Authorization, Science, EUA, FDA, Lilly, AD, Blood, AAIC, EST, Patient, Conference, Baozou Big News Events, Nature Communications, Publication, Corporation, CEO, GAAP, Lund, Plasma, Dementia, Pharmaceutical industry, Management, Self storage, Medical device, Medical imaging

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.
  • Quanterix had $399.0 million in cash, cash equivalents and restricted cash on the balance sheet as of December 31, 2021.
  • Quanterix Simoa technology was highlighted in a record 465 new publications in 2021, bringing total Simoa-specific inclusions to over 1,585.
  • In conjunction with this announcement, Quanterix Corporation will host a conference call on March 1, 2022 at 8:30 a.m. EST.

Quanterix Announces Executive Leadership Succession Plan

Retrieved on: 
Tuesday, March 1, 2022
Technology, Research, Other Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, University of Texas System, U.S. Securities and Exchange Commission, Board of directors, Proteomics, Population, Risk, Growth, Board, Cardiology, Bundhit Eua-arporn, Abbott, Eli Lilly, Roman Hrusovsky, Inflammation, NASDAQ, Biochemistry, Plasma, University, PerkinElmer, Industry, Company, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Infection, Medicine, Private Securities Litigation Reform Act, Senior, Science, News, Leadership, FDA, Forward-looking statement, Quality of life, Technology, Corporation, COVID, Neurology, IPO, Research, CEO, Buffalo, Longevity, Management, Pharmaceutical industry, Diagnosis, Toloue-4

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its executive leadership succession plan designed to leverage the Companys strong foundation for growth.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its executive leadership succession plan designed to leverage the Companys strong foundation for growth.
  • Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board and President Masoud Toloue will succeed Hrusovsky as CEO and join Quanterix Board of Directors.
  • Toloue has served as President of Quanterix and Diagnostics since June 2021 and has spent considerable time with Hrusovsky meeting key customers, partners and investors.
  • Quanterix is very well positioned to make the promise of earlier, non-invasive disease interception across multiple diseases a reality.

Quanterix to Participate in the SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 9, 2022
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Private Securities Litigation Reform Act, News, Longevity, Science, Conference, Research, Neurology, Inflammation, Quality of life, Technology, Corporation, U.S. Securities and Exchange Commission, EST, Population, Infection, Roman Hrusovsky, Cardiology, Webcast, Risk, Forward-looking statement

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on Feb. 16 at 4:20 p.m., EST.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on Feb. 16 at 4:20 p.m., EST.
  • A live webcast of the presentation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations .
  • Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
  • Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health.

UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology

Retrieved on: 
Monday, February 7, 2022
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Private Securities Litigation Reform Act, News, University College London, Plasma, Digital technology, Longevity, Biomarker, Neurodegeneration, DRI, Science, Doctor of Philosophy, Research, PPH, Company, Neurology, Inflammation, Quality of life, Knowledge, Technology, Dementia, Patient, Risk, Corporation, U.S. Securities and Exchange Commission, Diagnosis, Population, Infection, Founder, Roman Hrusovsky, Therapy, UCL, Government budget balance, Disease, Cardiology, Pathology, Ageing, Pressure, Forward-looking statement, Pharmaceutical industry, Medical imaging, MD

Alzheimers diagnosis is most often made late in the disease pathology after some level of cognitive impairment has already presented.

Key Points: 
  • Alzheimers diagnosis is most often made late in the disease pathology after some level of cognitive impairment has already presented.
  • He credits Quanterix Simoa technology and global PPH collaboration for significantly accelerating his progress on biomarker development and transforming our understanding of Alzheimers to inform development of early tests for dementia.
  • The podcast will provide a first look at the UK DRI Biomarker Factory research, including the next generation Simoa technology which the Company plans to make available later this year via the Quanterix Accelerator Laboratory.
  • The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Quanterix’ Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis

Retrieved on: 
Wednesday, January 26, 2022
Oncology, Health, Infectious Diseases, Other Health, Research, Science, Cardiology, Serum, Infection, Seroconversion, Rheumatology, Treatment, Roman Hrusovsky, Cytomegalovirus, Research, Quality of life, Patient, Epstein–Barr virus, EBV, Private Securities Litigation Reform Act, News, Association, Population, European Committee on Radiation Risk, Public health, Risk, Blood, Virus, Multiple sclerosis, Prevalence, Molecular mimicry, Cardiology, AFL, Diagnosis, Minuteman Library Network, Corporation, NASDAQ, Harvard University, Plasma, Harvard T.H. Chan School of Public Health, Congress, Technology, Neurology, Nature, National, Longevity, MS, Inflammation, EBNA1, Disease, Forward-looking statement, U.S. Securities and Exchange Commission, CNS, PPH, Founder, Pharmaceutical industry, Medical imaging, Online shopping, Science

Their analysis produced evidence that EBV increases susceptibility toward developing MS and supports the virus association with the pathogenesis of MS.

Key Points: 
  • Their analysis produced evidence that EBV increases susceptibility toward developing MS and supports the virus association with the pathogenesis of MS.
  • Part of what makes MS so devastating is that it often goes unrecognized for years or is mistaken for other neurological conditions.
  • Quanterix technology recently supported 31 scientific presentations at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the worlds largest meeting dedicated to advancing research for MS.
  • The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Quanterix Provides Operational and Preliminary Financial Highlights

Retrieved on: 
Thursday, January 13, 2022
Research, Pharmaceutical, Oncology, Technology, Infectious Diseases, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Other Technology, Health, Other Science, Research, Neurodegeneration, Private Securities Litigation Reform Act, Donanemab, Science, NASDAQ, Plasma, Neuro, Emergency Use Authorization, BBC, Efficiency, Diagnosis, Lilly, Telecommunication, Technology, Tau, Dementia, Conference, Publication, PET, Abbott, COVID-19, Risk, Eli Lilly, Infection, Company, Deloitte, Corporation, FDA, CCO, Lund, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, News, Inflammation, Cardiology, Viral Research and Diagnostic Laboratories, Solution, EST, Roman Hrusovsky, Review, PST, Lund University, Biogen, Longevity, Antibody, Population, Quality of life, Pathology, Data, EMERGE, Neurology, Omicron, University, Interview, Pharmaceutical industry, Medical device, Medical imaging, Management

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.
  • Quanterix pTau-181 assay was granted Breakthrough Device Designation from the U.S. FDA as an aid in the diagnosis of Alzheimers disease.
  • Quanterix Simoa technology was highlighted in a record 465 new publications in 2021, bringing total Simoa-specific inclusions to over 1,585.
  • Hired President and CCO in 2021 to accelerate the operational scaling of Quanterix RUO opportunity and to catalyze the symbiotic relationship between Research and Diagnostic.

Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 17, 2021
Research, FDA, Cardiology, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Research, Private Securities Litigation Reform Act, News, CEO, AFL, Emergency Use Authorization, Technology, Biomarker, Publication, Forward-looking statement, Company, Population, Plasma, Lists of diseases, Neurodegeneration, Diagnosis, Health, List, Inflammation, Cardiology, Blood, Eli Lilly and Company, Longevity, COVID-19, Roman Hrusovsky, U.S. Securities and Exchange Commission, Nature Communications, Lilly, Deloitte Technology Fast 500, Deloitte, Telecommunication, Science and technology in Asia, Corporation, AAIC, Organization, Neurology, Antibody, FDA, Science, Infection, EUA, NASDAQ, Quality of life, Pharmaceutical industry, Accounting, the 2021 Deloitte Technology Fast 500™, Quanterix, Deloitte, THE 2021 DELOITTE TECHNOLOGY FAST 500™, QUANTERIX, DELOITTE

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
  • This marks the fourth consecutive year Quanterix has been named to the Technology Fast 500.
  • Each year the Technology Fast 500 shines a light on leading innovators in technology and this year is no exception, said Paul Silverglate , vice chair, Deloitte LLP and U.S. technology sector leader.
  • Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies both public and private in North America.